Business Description
Astria Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US14875P1075
Description
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 749.33 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 43.1 | |||||
| 3-Year EPS without NRI Growth Rate | 46.1 | |||||
| 3-Year FCF Growth Rate | 40.2 | |||||
| 3-Year Book Growth Rate | -33.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.73 | |||||
| Quick Ratio | 21.73 | |||||
| Cash Ratio | 21.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -130.6 | |||||
| Shareholder Yield % | 0.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -34.36 | |||||
| ROA % | -33 | |||||
| ROIC % | -1135.32 | |||||
| ROC (Joel Greenblatt) % | -10302.4 | |||||
| ROCE % | -31.96 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.93 | |||||
| Price-to-Tangible-Book | 3.8 | |||||
| EV-to-EBIT | -6.31 | |||||
| EV-to-EBITDA | -6.31 | |||||
| EV-to-FCF | -6.26 | |||||
| Price-to-Net-Current-Asset-Value | 3.92 | |||||
| Price-to-Net-Cash | 1.89 | |||||
| Earnings Yield (Greenblatt) % | -15.85 | |||||
| FCF Yield % | -11.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Astria Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 1.263643 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 7.56 - 21.9 | ||
| Shares Outstanding (Mil) | 12.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Astria Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Astria Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Astria Therapeutics Inc Frequently Asked Questions
What is Astria Therapeutics Inc(STU:2090)'s stock price today?
The current price of STU:2090 is €7.57. The 52 week high of STU:2090 is €21.90 and 52 week low is €7.56.
When is next earnings date of Astria Therapeutics Inc(STU:2090)?
The next earnings date of Astria Therapeutics Inc(STU:2090) is 2024-05-10 Est..
Does Astria Therapeutics Inc(STU:2090) pay dividends? If so, how much?
Astria Therapeutics Inc(STU:2090) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers